All In Biotech

Drug Trial Radar · NCT07549698

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 17, 2026

Primary completion

Dec 2033

Study completion Dec 2033

Sponsor

Lead sponsor
CRISPR Therapeutics AGIndustry
Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).

Conditions

  • Warm Autoimmune Hemolytic Anemia (WAIHA)
  • ITP - Immune Thrombocytopenia
  • Warm Autoimmune Hemolytic Anemia
  • Immune Thrombocytopenic Purpura

Interventions

  • CTX112Biological

    CTX112 (zugo-cel): CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA.Time frame: From CTX112 infusion up to 28 days post infusion.

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Universitaetsklinikum Koeln

    Cologne, Germany · Recruiting

  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Medizinische Hochschule Hannover (MHH)

    Hanover, Germany · Recruiting

  • UCT University Medical Center Mainz

    Mainz, Germany · Recruiting

  • Hospital Clinic Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Reina Sofia

    Córdoba, Spain · Recruiting

  • Gregorio Marañón General University Hospital

    Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.